Antitumoral activity of 1,2-diaminocyclohexane derivatives in breast, colon and skin human cancer cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 World Health Organization. Cancer. Fact sheet N. 297. www.who.int/mediacentre/factsheets/fs297/en/.
  Google Scholar
• 2 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int. J. Cancer 136, 359–386 (2015).
  Medline CASGoogle Scholar
• 3 World Health Organization. Breast cancer: prevention and control. www.who.int/cancer/detection/breastcancer/en/.
  Google Scholar
• 4 Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breat Cancer Res. Treat. 83, 249–289 (2004).
  Medline CASGoogle Scholar
• 5 Catalano S, Campana A, Giordano C et al. Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: implications for targeted therapy. Clin. Cancer Res. 22(9), 2271–2282 (2016).
  Medline CASGoogle Scholar
• 6 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 7 Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl Acad. Sci. USA 91, 6319–6323 (1994).
  Medline CASGoogle Scholar
• 8 Ferreira HJ, Heyn H, Moutinho C, Esteller M. CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer. RNA Biology 9(6), 881–890 (2012).
  Medline CASGoogle Scholar
• 9 World Health Organization. Ultraviolet radiation and the INTERSUN Programme. www.who.int/uv/faq/skincancer/en/index1.html.
  Google Scholar
• 10 Nahar VK, Allison Ford M, Brodell RT et al. Skin cancer prevention practices among malignant melanoma survivors: a systematic review. J. Cancer Res. Clin. Oncol. 142(6), 1273–1283 (2016).
  Medline CASGoogle Scholar
• 11 Su DM, Zhang Q, Wang X et al. Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol. Cancer Ther. 8, 1292–1304 (2009).
  Medline CASGoogle Scholar
• 12 Paulitschke V, Haudek-Prinz V, Griss J et al. Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J. Proteome Res. 12, 3264–3276 (2013).
  Medline CASGoogle Scholar
• 13 Dinesh NVS, Bhupathiraju K, Grac M, Vicente H. Synthesis of carborane-containing porphyrin derivatives for the boron neutron capture therapy of tumors. Top. Heterocycl. Chem. 34, 31–52 (2015).
  Google Scholar
• 14 Foss MH, Pou S, Davidson PM et al. Diphenylether-modified 1,2-diamines with improved drug properties for development against mycobacterium tuberculosis. ACS Infect. Dis. 2(7), 500–508 (2016).
  Medline CASGoogle Scholar
• 15 Kim H, So SM, Chin J. Preparation of chiral diamines by the diaza-cope rearrangement (DCR). Aldrichimica ACTA 41, 77–88 (2008).
  Google Scholar
• 16 Gao J, Liu YG, Zhou Y. Chiral salicyl diamines. ChemMedChem 2, 1723–1729 (2007). • An interesting research article regarding diamine open compounds’ synthesis.
  Medline CASGoogle Scholar
• 17 Gao J, Liu YG, Zingaro RA. Cytotoxic activities, celular uptake, gene regulation, and optical imaging of novel platinum (II) complexes. Chem. Res. Toxicol. 22, 1705–1712 (2009). • An interesting research article regarding diamine open compounds’ biological effect.
  Medline CASGoogle Scholar
• 18 O'Connell KM, Beckmann HS, Laraia L et al. A two-directional strategy for the diversity-oriented synthesis of macrocyclic scaffolds. Org. Biomol. Chem. 10, 7545–7551 (2012).
  MedlineGoogle Scholar
• 19 Collins S, Bartlett S, Nie F et al. Diversity-oriented synthesis of macrocycle libraries for drug discovery and chemical biology. Synthesis 48(10), 1457–1473 (2016). • Interesting review regarding the role of macrocycles in drug discovery.
  CASGoogle Scholar
• 20 Balderas-Rentería R, González-Barranco P, García A, Banik BK, Rivera G. Anticancer drug design using scaffolds of β-lactams, sulfonamides, quinoline, quinoxaline and natural products. Drug advances in clinical trials. Curr. Med. Chem. 19, 4377–4398 (2012).
  Medline CASGoogle Scholar
• 21 Conejo-García A, Campos JM, Sánchez-Martín RM, Gallo MA, Espinosa A. Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors. J. Med. Chem. 46, 3754–3757 (2003). • Published work by us, related to macrocycle research.
  Medline CASGoogle Scholar
• 22 Trousil S, Kaliszczak M, Schug Z et al. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget 7(24), 37103–37120 (2016).
  MedlineGoogle Scholar
• 23 Rubio-Ruiz B, Figuerola-Conchas A, Ramos-Torrecillas J et al. Discovery of a New binding site on human choline kinase α 1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivative. J. Med. Chem. 57, 507–515 (2014).
  Medline CASGoogle Scholar
• 24 Schiaffino-Ortega S, Baglioni E, Mariotto E et al. Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1). Sci. Rep. 6, 23793 (2016).
  MedlineGoogle Scholar
• 25 Saniger E, Campos JM, Entrena A et al. Neighbouring-group participation as the key step in the reactivity of acyclic and cyclic salicyl-derived O, O-acetals with 5-fluorouracil. Antiproliferative activity, cell cycle dysregulation and apoptotic induction of new O, N-acetals against breast cancer cells. Tetrahedron 59, 8017–8026 (2003).
  CASGoogle Scholar
• 26 López-Cara LC, Conejo-García A, Marchal JA et al. New (RS)-benzoxazepinpurines with anti-tumour activity: the chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine. Eur. J. Med. Chem. 46, 249–258 (2011).
  Medline CASGoogle Scholar
• 27 Marchal JA, Carrasco E, Ramírez A et al. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence. Drug Des. Devel. Ther. 7, 1301–1313 (2013).
  MedlineGoogle Scholar
• 28 Ramírez A, Boulaiz H, Morata-Tarifa C et al. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. Oncotarget 5, 3590–3606 (2014).
  MedlineGoogle Scholar
• 29 Powell WH, Weissbach O. Phane nomenclature. Part I: Phane parent names (IUPAC Recommendations 1998). Pure Appl. Chem. 70, 1513–1545 (1998).
  CASGoogle Scholar
• 30 Favre HA, Hellwinkel D, Powell WH, Smith HA. Phane nomenclature. Part II: modification of the degree of hydrogenation and substitution derivatives of phane parent hydrides (IUPAC recommendations 2002). Pure Appl. Chem. 74, 809–834 (2002).
  CASGoogle Scholar
• 31 Simion C, Simion A, Mitoma Y et al. Synthesis of new dihydroxy-dioxygenated ortho-[2,x] cyclophanes. Heterocycles 53, 2459–2470 (2000). •• An interesting research article regarding macrocycle compound's synthesis.
  CASGoogle Scholar
• 32 Fernández-Fernández MC, Bastida de la Calle R, Macías A, Valencia-Matarranz L, Pérez-Lourido P. Co(II), Ni(II) and Cu(II) complexes of new [1+1] and [2+2] macrocyclic ligands derived from 1,4-bis(2′-formylphenyl)-1,4-dioxabutane and cis-1,2-diaminocyclohexane. Polyhedron 27, 2301–2308 (2008).
  CASGoogle Scholar
• 33 Correa WH, Scott JL. Synthesis and characterisation of macrocyclic diamino chiral crown ethers. Molecules 9, 513–519 (2004).
  Medline CASGoogle Scholar
• 34 Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl Cancer Inst. 51(5), 1409–1416 (1973).
  Medline CASGoogle Scholar
• 35 Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 41(5), 1751–1756 (1981).
  Medline CASGoogle Scholar
• 36 Giard DJ, Aaronson SA, Todaro GT et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51, 1417–1423 (1973).
  Medline CASGoogle Scholar
• 37 Liua F, Zhoua Z, Gou S, Jian Zhaoab J, Chenab F. Synthesis and antiproliferative activity of (1R,2R)-N1-(2-butyl)-1,2-cyclohexanediamine platinum(II) complexes with malonate derivatives. J. Coord. Chem. 67(17), 2858–2866 (2014).
  Google Scholar
• 38 Chen P, Lee NV, Hu W et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol. Cancer Ther. 15(10), 2273–2281 (2016).
  Medline CASGoogle Scholar
• 39 Flaherty KT, Lorusso PM, Demichele A et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res. 18, 568–576 (2012).
  Medline CASGoogle Scholar
• 40 Roberts PJ, Bisi JE, Strum JC et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J. Natl Cancer Inst. 104, 476–487 (2012).
  Medline CASGoogle Scholar
• 41 Kubo M, Kanaya N, Petrossian K et al. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res. Treat. 137, 93–107 (2013).
  Medline CASGoogle Scholar
• 42 Tate CR, Rhodes LV, Segar HC et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 14, R79 (2012). •• Highlights the mechanism of the antitumor effect of panobinostat, a histone deacetylase inhibitor that provokes cell cycle G2/M arrest, as (±)-trans-1.
  Medline CASGoogle Scholar
• 43 Fortunati N, Catalano MG, Marano F et al. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res. Treat. 124, 667–675 (2010).
  Medline CASGoogle Scholar
• 44 Marchal JA, Boulaiz H, Suárez I et al. Growth inhibition, G1-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest. New Drug 22, 379–389 (2004).
  Medline CASGoogle Scholar
• 45 Kamil Rudolf K, Emil Rudolf E. Antiproliferative effects of α-tomatine are associated with different cell death modalities in human colon cancer cells. J. Funct. Foods 27, 491–502 (2016).
  Google Scholar
• 46 Kurita M, Hanada S, Ichimaru Y et al. Indirubin 3′-epoxide induces caspase-independent cell death in human neuroblastoma. Biol. Pharm. Bull. 39, 993–999 (2016).
  Medline CASGoogle Scholar
• 47 Nicolaoua KA, Liapisb V, Evdokioub A et al. Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells. Biochem. Biophys. Res. Commun. 425(1), 76–82 (2012).
  MedlineGoogle Scholar